Trial: BMD5
Aspirin Events/Patients (%): 91/3,429
(2.65)
Control Events/Patients (%): 39/1,710
(2.28)
Odds Ratio (95% CI): 1.17 (0.80 to 1.71)
Duration of Therapya: 5.8 years
Annual Risk for Stroke Among Control Patients: 0.39%
Vascular Events Avoided per 1,000 Patients Treated per Year: 0.6 excess events
Trial: PHS4
Aspirin Events/Patients (%): 119/11,037
(1.08)
Control Events/Patients (%): 98/11,034
(0.89)
Odds Ratio (95% CI): 1.22 (0.93 to 1.59)
Duration of Therapya: 5 years
Annual Risk for Stroke Among Control Patients: 0.18%
Vascular Events Avoided per 1,000 Patients Treated per Year: 0.4 excess events
Trial: TPT7
Aspirin Events/Patients (%): 18/1,268
(1.42)
Control Events/Patients (%): 26/1,272
(2.04)
Odds Ratio (95% CI): 0.69 (0.38 to 1.27)
Duration of Therapya: 6.8 years
Annual Risk for Stroke Among Control Patients: 0.30%
Vascular Events Avoided per 1,000 Patients Treated per Year: 0.9
Trial: HOT8
Aspirin Events/Patients (%): 146/9,399
(1.55)
Control Events/Patients (%): 148/9,391
(1.58)
Odds Ratio (95% CI): 0.99 (0.78 to 1.24)
Duration of Therapya: 3.8 years
Annual Risk for Stroke Among Control Patients: 0.41%
Vascular Events Avoided per 1,000 Patients Treated per Year: 0.1
Trial: PPP9
Aspirin Events/Patients (%): 16/2,226
(0.72)
Control Events/Patients (%): 24/2,269
(1.06)
Odds Ratio (95% CI): 0.68 (0.36 to 1.28)
Duration of Therapya: 3.6 years
Annual Risk for Stroke Among Control Patients: 0.29%
Vascular Events Avoided per 1,000 Patients Treated per Year: 0.9
*BMD indicates British Male Doctors' Trial; HOT, Hypertension Optimal Treatment Trial; PHS, Physicians' Health Study; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial.
aValues given are means except for the TPT value, which is the median.